Degreef 2014.

Methods	Single‐centre Belgian study Randomised controlled clinical trial Study period not stated
Participants	30 participants 26 male:4 female Mean age: 63.5 (SD 8) years Inclusion criteria: Adult patients scheduled for subtotal fasciectomy to treat Dupuytren's disease were eligible for inclusion if they had a D score > 4 Exclusion criteria: patients undergoing a reintervention for recurrent contractures; patients with a need for skin grafts or flaps; premenopausal women; patients using anti‐inflammatory drugs; patients with a history of malignancy; patients with a known allergy to tamoxifen
Interventions	Segmental fasciectomy with 80 mg oral tamoxifen daily for 6 weeks before surgery continuing until 12 weeks after surgery vs Segmental fasciectomy with 80 mg oral placebo daily for 6 weeks before surgery continuing until 12 weeks after surgery
Outcomes	Improvement in extension deficit by joint No differences at MCPJ at 3 months, 12 months or 24 months; significantly greater differences for tamoxifen group at PIPJ at 3 months and 12 months; not significantly different at 24 months Tubiana index Significantly greater differences in tamoxifen group at 3 months; not significantly different at 12 months nor 24 months Satisfaction visual analogue scale Significantly higher in tamoxifen group at 3 months; no significant differences at 12 months or 24 months Hand function (DASH) No significant differences at 12 months nor 24 months
Notes	Length of follow‐up: 24 months Low‐quality evidence, as inadequate details on study design and imprecision Funding source: Belgian Orthopaedic Society
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Inadequate detail: not described
Allocation concealment (selection bias)	Unclear risk	Inadequate detail: boxes used to store allocation, but opacity not described; second copies of allocations stored in envelopes with inadequate details provided
Incomplete outcome data (attrition bias) All outcomes	Low risk	Attrition described; systematic differences between groups unlikely
Selective reporting (reporting bias)	Unclear risk	No data presented for hand function (DASH) at 3 months
Other bias	Low risk	Blinded study; hence blocked randomisation not problematic
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double‐blind
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Blinded outcome measurements